NASDAQ:AERI - Aerie Pharmaceuticals Stock Price, Forecast & News

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals Inc (NASDAQ:AERI) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.86) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.02. The company earned $18.54 million during the quarter, compared to analyst estimates of $17.59 million. Aerie Pharmaceuticals had a negative net margin of 328.34% and a negative return on equity of 77.63%. View Aerie Pharmaceuticals' Earnings History.

Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Aerie Pharmaceuticals.

13 brokerages have issued 12 month price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $25.00 to $56.00. On average, they expect Aerie Pharmaceuticals' share price to reach $40.77 in the next twelve months. This suggests a possible upside of 79.3% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.

Press coverage about AERI stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Aerie Pharmaceuticals.

Aerie Pharmaceuticals saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 13,290,000 shares, a decrease of 9.6% from the December 15th total of 14,700,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is presently 11.8 days. Currently, 35.2% of the company's shares are short sold. View Aerie Pharmaceuticals' Current Options Chain.

Some companies that are related to Aerie Pharmaceuticals include Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX) and Editas Medicine (EDIT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Incyte (INCY), Plug Power (PLUG) and Alibaba Group (BABA).

Aerie Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.51%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.

AERI stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Aerie Pharmaceuticals.

AERI stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AERI stock can currently be purchased for approximately $22.74.

Aerie Pharmaceuticals has a market capitalization of $1.05 billion and generates $24.18 million in revenue each year. The company earns $-232,570,000.00 in net income (profit) each year or ($4.65) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.View Additional Information About Aerie Pharmaceuticals.

The official website for Aerie Pharmaceuticals is http://www.aeriepharma.com/.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]